{"id":959324,"date":"2026-05-06T18:55:39","date_gmt":"2026-05-06T22:55:39","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchenne-muscular-dystrophy-treated-with-entr-601-44-in-phase-1-2-elevate-44-201-study-on-may-7-2026\/"},"modified":"2026-05-06T18:55:39","modified_gmt":"2026-05-06T22:55:39","slug":"entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchenne-muscular-dystrophy-treated-with-entr-601-44-in-phase-1-2-elevate-44-201-study-on-may-7-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchenne-muscular-dystrophy-treated-with-entr-601-44-in-phase-1-2-elevate-44-201-study-on-may-7-2026\/","title":{"rendered":"Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1\/2 ELEVATE-44-201 Study on May 7, 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p>BOSTON, May  06, 2026  (GLOBE NEWSWIRE) &#8212; Entrada Therapeutics, Inc. (Nasdaq: TRDA) will announce topline results from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose portion of the Phase 1\/2 ELEVATE-44-201 clinical study of ENTR-601-44 on Thursday, May 7, 2026. The Company will host an investor webcast and conference call at 8:30 a.m. ET to discuss these clinical results.<\/p>\n<p>The webcast can be accessed by visiting the Investor Relations section of the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Hm_sqvQHt66GyDYH6CUF7C4g7Gn31ZyB0Wf05BuvpE6A4xY1L_48WWKV22HE2XGYFT58whsIKPYUZaFU_mr5-XaL_ctELc3k-7QypxR7vQ8=\" rel=\"nofollow\" target=\"_blank\">www.entradatx.com<\/a>. Analysts planning to participate during the Q&amp;A portion of the live call can join the conference call at the audio-conferencing link <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EBZyFONg-4h63tzyMqDEzC66q4OqTPmH4p-cBVhpQwHgXtBfrV835D1eLpGTOejkWlBmWA7dpSXCJwYrZnVfwUtudtVYBoJw51KdzHDrb_G_Ai5RmPHh4obC8CL89Q7NxCpGyjUEZJTkM7z5TIXPGKP6ETY1NSahB8Eii9nv8YU=\" rel=\"nofollow\" target=\"_blank\">here<\/a>. The webcast will be archived and available for replay on the Entrada Therapeutics website for 90 days following the call.<\/p>\n<p>\n        <strong>About Entrada Therapeutics<\/strong><br \/>\n        <br \/>Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of genetic medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary, versatile and modular approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company\u2019s lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.<\/p>\n<p>For more information about Entrada, please visit our website, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Hm_sqvQHt66GyDYH6CUF7F97k7fQSQYSqc1T-At4ntwqFSU98VZJZjDs9bl3kkdE3hJqXDoi8iEFfQajUAnbq-qNNquIkJz-7hqjcuFbl_g=\" rel=\"nofollow\" target=\"_blank\">www.entradatx.com<\/a>, and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zdsZc0f-LmoSTbokattshgOp3v3rABHsEh_C8hoRQ8XEEyofLJg_42ejgSuRO1FfmRG1P8FhJheInFY8Y7L26UWi5HtcnGAqvqOtNkY6W-Ti3gUNz7JMrN6yzwUODgWKlshiCYc7ZG39xLVzZO0C0V4zLtmTKd1jlADyLknHx-zJ4umga4Rf5nCaWljhpQmdIrmFYvwR_kZirH2jkY4vyK7Tbi4LuycfGi0t49ledMu0FrQQZXtwW_ueobUChuK4\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Karla MacDonald<br \/>Chief Corporate Affairs Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=N3F0YJBr8CLMe4MDIKdV0R2ay80DbhdoagNVVPC0Vvaro4japmtBP1jg5LSsY4rgjMHhBsGXZCEIyhxwzusmwF_0cxbYsVzFULj8EDWrSDms7UsHBV3UUPUvv49SBplA\" rel=\"nofollow\" target=\"_blank\">kmacdonald@entradatx.com<\/a><\/p>\n<p>\n        <strong>Patient Advocacy Contact<\/strong><br \/>\n        <br \/>Sarah Friedhoff<br \/>Head of Patient Advocacy<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=z4YYHSV_XaHk5e-Us3kpiyB423A3X3HrJA-L1RBIuemnn9OrBUjpBe7Jc7zz7cCR8by4eDkPEc4LKf0VfwGChw2ssVvZioPacFyMCR7rCyA6QEwJijaDskbLFDY-GvyE\" rel=\"nofollow\" target=\"_blank\">patientadvocacy@entradatx.com<\/a><\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Megan Prock McGrath<br \/>CTD Comms, LLC<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Vmg7f_KNfSGsk6zqZIgkFDnIQzBMoq5aLyJgQ-aVYemKgAbfoOOsYIqQ6vn9oMWNzmC7Qfpzskv3k8_61DXD8dtvBzyd0me7irkSwFrnwTI=\" rel=\"nofollow\" target=\"_blank\">megan@ctdcomms.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNDQ1NSM3NTg2OTIxIzIyMDA1MzI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YjhiYzRkNmMtOWU0ZS00YmUyLTlhMzgtMzUyOGVlNGVmNzgzLTEyMTIwODUtMjAyNi0wNS0wNi1lbg==\/tiny\/Entrada-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, May 06, 2026 (GLOBE NEWSWIRE) &#8212; Entrada Therapeutics, Inc. (Nasdaq: TRDA) will announce topline results from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose portion of the Phase 1\/2 ELEVATE-44-201 clinical study of ENTR-601-44 on Thursday, May 7, 2026. The Company will host an investor webcast and conference call at 8:30 a.m. ET to discuss these clinical results. The webcast can be accessed by visiting the Investor Relations section of the Company\u2019s website at www.entradatx.com. Analysts planning to participate during the Q&amp;A portion of the live call can join the conference call at the audio-conferencing link here. The webcast will be archived and available for replay on the Entrada Therapeutics website for 90 days following the call. About &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchenne-muscular-dystrophy-treated-with-entr-601-44-in-phase-1-2-elevate-44-201-study-on-may-7-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1\/2 ELEVATE-44-201 Study on May 7, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-959324","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1\/2 ELEVATE-44-201 Study on May 7, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchenne-muscular-dystrophy-treated-with-entr-601-44-in-phase-1-2-elevate-44-201-study-on-may-7-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1\/2 ELEVATE-44-201 Study on May 7, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, May 06, 2026 (GLOBE NEWSWIRE) &#8212; Entrada Therapeutics, Inc. (Nasdaq: TRDA) will announce topline results from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose portion of the Phase 1\/2 ELEVATE-44-201 clinical study of ENTR-601-44 on Thursday, May 7, 2026. The Company will host an investor webcast and conference call at 8:30 a.m. ET to discuss these clinical results. The webcast can be accessed by visiting the Investor Relations section of the Company\u2019s website at www.entradatx.com. Analysts planning to participate during the Q&amp;A portion of the live call can join the conference call at the audio-conferencing link here. The webcast will be archived and available for replay on the Entrada Therapeutics website for 90 days following the call. About &hellip; Continue reading &quot;Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1\/2 ELEVATE-44-201 Study on May 7, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchenne-muscular-dystrophy-treated-with-entr-601-44-in-phase-1-2-elevate-44-201-study-on-may-7-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-06T22:55:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNDQ1NSM3NTg2OTIxIzIyMDA1MzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchenne-muscular-dystrophy-treated-with-entr-601-44-in-phase-1-2-elevate-44-201-study-on-may-7-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchenne-muscular-dystrophy-treated-with-entr-601-44-in-phase-1-2-elevate-44-201-study-on-may-7-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1\\\/2 ELEVATE-44-201 Study on May 7, 2026\",\"datePublished\":\"2026-05-06T22:55:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchenne-muscular-dystrophy-treated-with-entr-601-44-in-phase-1-2-elevate-44-201-study-on-may-7-2026\\\/\"},\"wordCount\":294,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchenne-muscular-dystrophy-treated-with-entr-601-44-in-phase-1-2-elevate-44-201-study-on-may-7-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNDQ1NSM3NTg2OTIxIzIyMDA1MzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchenne-muscular-dystrophy-treated-with-entr-601-44-in-phase-1-2-elevate-44-201-study-on-may-7-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchenne-muscular-dystrophy-treated-with-entr-601-44-in-phase-1-2-elevate-44-201-study-on-may-7-2026\\\/\",\"name\":\"Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1\\\/2 ELEVATE-44-201 Study on May 7, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchenne-muscular-dystrophy-treated-with-entr-601-44-in-phase-1-2-elevate-44-201-study-on-may-7-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchenne-muscular-dystrophy-treated-with-entr-601-44-in-phase-1-2-elevate-44-201-study-on-may-7-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNDQ1NSM3NTg2OTIxIzIyMDA1MzI=\",\"datePublished\":\"2026-05-06T22:55:39+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchenne-muscular-dystrophy-treated-with-entr-601-44-in-phase-1-2-elevate-44-201-study-on-may-7-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchenne-muscular-dystrophy-treated-with-entr-601-44-in-phase-1-2-elevate-44-201-study-on-may-7-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchenne-muscular-dystrophy-treated-with-entr-601-44-in-phase-1-2-elevate-44-201-study-on-may-7-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNDQ1NSM3NTg2OTIxIzIyMDA1MzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNDQ1NSM3NTg2OTIxIzIyMDA1MzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchenne-muscular-dystrophy-treated-with-entr-601-44-in-phase-1-2-elevate-44-201-study-on-may-7-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1\\\/2 ELEVATE-44-201 Study on May 7, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1\/2 ELEVATE-44-201 Study on May 7, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchenne-muscular-dystrophy-treated-with-entr-601-44-in-phase-1-2-elevate-44-201-study-on-may-7-2026\/","og_locale":"en_US","og_type":"article","og_title":"Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1\/2 ELEVATE-44-201 Study on May 7, 2026 - Market Newsdesk","og_description":"BOSTON, May 06, 2026 (GLOBE NEWSWIRE) &#8212; Entrada Therapeutics, Inc. (Nasdaq: TRDA) will announce topline results from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose portion of the Phase 1\/2 ELEVATE-44-201 clinical study of ENTR-601-44 on Thursday, May 7, 2026. The Company will host an investor webcast and conference call at 8:30 a.m. ET to discuss these clinical results. The webcast can be accessed by visiting the Investor Relations section of the Company\u2019s website at www.entradatx.com. Analysts planning to participate during the Q&amp;A portion of the live call can join the conference call at the audio-conferencing link here. The webcast will be archived and available for replay on the Entrada Therapeutics website for 90 days following the call. About &hellip; Continue reading \"Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1\/2 ELEVATE-44-201 Study on May 7, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchenne-muscular-dystrophy-treated-with-entr-601-44-in-phase-1-2-elevate-44-201-study-on-may-7-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-06T22:55:39+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNDQ1NSM3NTg2OTIxIzIyMDA1MzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchenne-muscular-dystrophy-treated-with-entr-601-44-in-phase-1-2-elevate-44-201-study-on-may-7-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchenne-muscular-dystrophy-treated-with-entr-601-44-in-phase-1-2-elevate-44-201-study-on-may-7-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1\/2 ELEVATE-44-201 Study on May 7, 2026","datePublished":"2026-05-06T22:55:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchenne-muscular-dystrophy-treated-with-entr-601-44-in-phase-1-2-elevate-44-201-study-on-may-7-2026\/"},"wordCount":294,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchenne-muscular-dystrophy-treated-with-entr-601-44-in-phase-1-2-elevate-44-201-study-on-may-7-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNDQ1NSM3NTg2OTIxIzIyMDA1MzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchenne-muscular-dystrophy-treated-with-entr-601-44-in-phase-1-2-elevate-44-201-study-on-may-7-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchenne-muscular-dystrophy-treated-with-entr-601-44-in-phase-1-2-elevate-44-201-study-on-may-7-2026\/","name":"Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1\/2 ELEVATE-44-201 Study on May 7, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchenne-muscular-dystrophy-treated-with-entr-601-44-in-phase-1-2-elevate-44-201-study-on-may-7-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchenne-muscular-dystrophy-treated-with-entr-601-44-in-phase-1-2-elevate-44-201-study-on-may-7-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNDQ1NSM3NTg2OTIxIzIyMDA1MzI=","datePublished":"2026-05-06T22:55:39+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchenne-muscular-dystrophy-treated-with-entr-601-44-in-phase-1-2-elevate-44-201-study-on-may-7-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchenne-muscular-dystrophy-treated-with-entr-601-44-in-phase-1-2-elevate-44-201-study-on-may-7-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchenne-muscular-dystrophy-treated-with-entr-601-44-in-phase-1-2-elevate-44-201-study-on-may-7-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNDQ1NSM3NTg2OTIxIzIyMDA1MzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNDQ1NSM3NTg2OTIxIzIyMDA1MzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchenne-muscular-dystrophy-treated-with-entr-601-44-in-phase-1-2-elevate-44-201-study-on-may-7-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1\/2 ELEVATE-44-201 Study on May 7, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/959324","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=959324"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/959324\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=959324"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=959324"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=959324"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}